Shigella flexneri serotype 3a (S. flexneri 3a)

Shigella flexneri serotype 3a is a specific serotype of the Gram-negative, facultative anaerobic bacterium Shigella flexneri, which is a leading causative agent of bacillary dysentery (shigellosis) globally, especially in developing regions [1, 5, 8]. This serotype is defined by the unique chemical structure of its O-antigen, a polysaccharide component of the outer membrane lipopolysaccharide (LPS) characterized by a rhamnose-based tetrasaccharide backbone with specific O-acetylation modifications [2, 4]. The O-antigen is the primary molecular target for the development of conjugate vaccines designed to provide serotype-specific protection [3, 6, 10]. Pathogenesis involves the use of a Type III secretion system (T3SS) to invade human colonic epithelial cells, followed by intracellular replication and rapid cell-to-cell dissemination via actin-based motility, resulting in intense inflammation and tissue destruction [5, 13]. While antibiotic treatment with agents such as ciprofloxacin or azithromycin can shorten the duration of illness, the emergence of 'superbug' strains and extensively drug-resistant (XDR) profiles in serotype 3a is a major clinical concern [7, 16]. Effective management increasingly relies on the development of multivalent vaccines to address the growing threat of antimicrobial resistance [9, 10, 11].

Other names

Sf3aShigella flexneri 3aS. flexneri serotype 3a

Antibiotics targeting this pathogen act by inhibiting bacterial DNA replication through DNA gyrase and topoisomerase IV interference (fluoroquinolones), inhibiting protein synthesis via the 50S ribosomal subunit (macrolides), or disrupting cell wall biosynthesis (beta-lactams). Additionally, conjugate vaccines targeting the serotype-specific O-antigen work by inducing humoral immunity and bactericidal antibodies to prevent mucosal invasion.